Biocon Limited has informed the Exchange regarding 'Notification to Stock Exchanges'.
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Biocon Pharma Limited, a wholly owned subsidiary of Biocon Limited, has received US FDA approval for its ANDA (Abbreviated New Drug Application) for Everolimus Tablets in strengths of 0.25 mg, 0.5 mg, 0.75 mg, and 1 mg. Everolimus is a prescription medication used to prevent organ rejection in adult patients who have undergone kidney or liver transplantation. The company stated that this approval will further strengthen Biocon's portfolio of vertically integrated, complex drug products. The approval positions Biocon to enter or expand its presence in the US generic market for this transplant-related therapy.
This is a positive development for Biocon as it expands the company's US generic product portfolio in a niche therapeutic area, potentially adding a new revenue stream. However, the financial impact will depend on the market size for generic Everolimus and competition from other generic manufacturers.